We are Homology

Our mission is focused on curing disease and transforming patients’ lives

“The talented team at Homology has a clear path forward with both its clinical and preclinical programs and remains dedicated and focused on bringing novel genetic medicines to patients who need them.”

Arthur Tzianabos, Ph.D.., Chair of the Board for Homology Medicines & Venture Partner, 5AM Ventures

Mobile image

Arthur Tzianabos, Ph.D.

Chair of the Board for Homology Medicines & Venture Partner, 5AM Ventures

Matthew Patterson

Executive Chair, Remix Therapeutics

Jeff Poulton, M.B.A.

Chief Financial Officer, Alnylam

Alise Reicin, M.D.

Chief Executive Officer, Tectonic Therapeutic

Steven Gillis, Ph.D.

Managing Director, ARCH Venture Partners

Mary Thistle

Special Advisor, Bill & Melinda Gates Medical Research Institute